Neoadjuvant Treatment in Resectable Pancreatic Cancer

NCT01900327 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-05-11

No results posted yet for this study

Summary

Sequential Neoadjuvant Chemoradiotherapy (CRT) Followed by Curative Surgery vs. Primary Surgery Alone for Resectable, Non-metastasized Pancreatic Adenocarcinoma

Conditions

Interventions

RADIATION

External Beam Radiation

Neoadjuvant CRT with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions.

DRUG

Gemcitabine neoadjuvant

weekly Gemcitabine 300mg/m2 for 6 weeks neoadjuvant

PROCEDURE

Surgery

Upfront pancreato-duodenectomy

DRUG

Gemcitabine adjuvant

Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator

Sponsors & Collaborators

  • University Hospital Schleswig-Holstein

    collaborator OTHER
  • Hannover Medical School

    collaborator OTHER
  • St. Josef Hospital Bochum

    collaborator OTHER
  • University of Jena

    collaborator OTHER
  • SRH Wald-Klinikum Gera GmbH

    collaborator OTHER
  • Klinikum Darmstadt

    collaborator OTHER
  • Universität des Saarlandes

    collaborator OTHER
  • Heidelberg University

    collaborator OTHER
  • Staedtisches Klinikum Karlsruhe

    collaborator OTHER
  • University Hospital Freiburg

    collaborator OTHER
  • University Hospital Regensburg

    collaborator OTHER
  • Technical University of Munich

    collaborator OTHER
  • University Hospital Augsburg

    collaborator OTHER
  • Klinikum Stuttgart

    collaborator OTHER
  • Ludwig-Maximilians - University of Munich

    collaborator OTHER
  • University of Rostock

    collaborator OTHER
  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Principal Investigators

  • Jakob R Izbicki, MD, FACS · Universitätsklinikum Hamburg-Eppendorf

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-11-22
Completion
2017-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01900327 on ClinicalTrials.gov